Scientists from San Jose State University report that they have turned to the opossum to develop a promising new and inexpensive antidote for poisonous snake bites. They predict it could save thousands of lives worldwide without the side effects of current treatments. The presentation will take place here at the 249th National Meeting & Exposition of the American Chemical Society (ACS).
Worldwide, an estimated 421,000 cases of poisonous snake bites and 20,000 deaths from these bites occur yearly, according to the International Society on Toxicology. Intriguingly, opossums shrug off snake bite venom with no ill effects. The team explains that initial studies showing the opossum’s immunity to snake venom were done in the 1940s and in the early 1990s, a group of researchers identified a serum protein from the opossum that was able to neutralize snake venoms. One researcher found that a smaller chain of amino acids from the opossum protein, called a peptide, was also able to neutralize the venom.
Armed with this information, the team had the peptide chemically synthesized. When they tested it in venom-exposed mice, they found that it protected them from the poisonous effects of bites from U.S. Western Diamondback rattlesnakes and Russell’s Viper venom from Pakistan. The exact mechanism is not known, but recently published computer models have shown that the peptide interacts with proteins in the snake venom that are toxic to humans. The team state that it appears that the venom protein may bind to the peptide, rendering it no longer toxic.
In the current study the team showed that they could program the bacteria E. coli to make the peptide. Producing the peptide in bacteria should enable the group to inexpensively make large quantities of it. The peptide should also be easy to purify from E. coli.
The team explain that their approach is different because most antivenoms are made by injecting the venom into a horse and then processing the serum. The serum has additional components, however, so the patient often has some kind of adverse reaction, such as a rash, itching, wheezing, rapid heart rate, fever or body aches. The peptide being used in the current study does not have those negative effects on mice.
Because the process is inexpensive, the antivenom has a good chance of being distributed to underserved areas across the globe, according to the team. That includes India, Southeast Asia, Africa and South America, where poisonous snakes bite thousands of people every year. The team state that based on the original publications, the antivenom would probably work against venoms from other poisonous snakes, as well as against scorpion, plant and bacterial toxins.
The team add that the new antivenom has another potential advantage in that it could be delivered in just one injectable dose. This is due to the fact that when a snake bites, it injects venom into the victim in different ways, depending on which part of the body is bitten and the angle of the bite, ergo each snake bite would and could be treated differently.
It is common that additional antivenom needs to be injected if the patient continues to show the effects of the venom. However, the team surmise that because the new antidote appears to have no side effects, at least in mice, it probably could be given in one large dose to attack all of the venom, making additional injections unnecessary. The team plans to test this theory soon. They also will make large quantities of the antivenom and test it on mice, using a wide variety of venoms and toxins.
Source: American Chemical Society (ACS)
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.